We investigated the epitope specificity of the produced anti-TG2 antibodies by applying a double mutant TG2 (R19S, E153S) devoid of epitope 2 [15] and proved that the vast majority of the emerging autoantibodies produced by CeD patients that appear in serum target the celiac epitope 2 on the N-terminal surface of TG2. This evidence concerns the gene TGM2 and cranioectodermal dysplasia.